The company said its revenue increased to $259 million, and that the increase was driven by accelerated momentum of the company's long-term growth strategy combined with the nonrecurring impact of customer site shutdowns in the comparative period related to the COVID-19 pandemic.

Net sales for the full fiscal year of 2021 increased 26% to $931 million, the company also reported.

The Protein Sciences segment, through which the company supplies specialized proteins such as cytokines and growth factors, immunoassays, antibodies, and reagents, reported fourth quarter 2021 net sales of $192.3 million, an increase of 51% from $127.3 million for the fourth quarter of fiscal 2020.

Bio-Techne also reported fourth quarter fiscal 2021 net sales of $67.1 million in its Diagnostics and Genomics segment, an increase of 38% from $48.7 million for the fourth quarter of fiscal 2020. This segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays, in situ hybridization products, and exosome-based diagnostics products.